Search results for: Pricing and Reimbursement
Filter search results
Around the World in HTA: Japan – An algorithmic approach to containing costs
14 April 2026
…MFN could bring significant implications for the Japanese pharmaceutical market, potentially affecting pricing and access to innovative medicines, and the overall exposure of Japan’s system to global pricing pressures. Japan’s…
Socio-Economic Value of Adult Immunisation Programmes
18 April 2024
…prevention mindset is often adopted in other sectors beyond healthcare (e.g. road safety and workforce health and safety) to prevent harmful health outcomes and productivity losses and promote societal well-being. Similarly,…
Is Rate Of Return Pricing A Useful Approach When Value-Based Pricing Is Not Appropriate?
22 March 2019
…in the United States: Pricing and Paying for Cures. OHE Seminar Briefing 25. RePEc. Marsden, G. and Towse, A., 2017. Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products:…
A NICE Wind of Change? The What and So What of the NICE Methods Consultation
7 December 2020
…in England and beyond. These are described and recommended on in our recently published report (Rodes Sanchez, Henderson and Steuten, 2020). In conclusion, NICE proposed changes to address a number…
Benefiting from the Promise of Personalised Medicine: Recent OHE Presentations
18 February 2014
…situation in England, including the context and current status of pricing and reimbursement decisions, issues that are peculiar to England’s approach, and others that are common across countries, including those…
Join OHE at ISPOR: MCDA, Risk Sharing and Value-Based Pricing
4 October 2011
…of a Centralized European Pricing and Reimbursement Agency,’ moderated by Mark Schulpher, University of York, and including also Hans-Georg Eichler, EMA. Should an agency similar in structure to EMA be…
Altering the trajectory of HIV in Europe
22 May 2025
…language, and are targeted at both general populations and healthcare professionals, have the potential to educate and reduce prejudice and stigma. Diversifying treatment options: PrEP and antiretroviral therapy (ART) are…
Around the world in HTAs: China – From fragmentation to function
2 September 2025
…informal and fragmented. In 2016 and 2017, the Ministry of Human Resources and Social Security and the National Health and Family Planning Commission (which is now the National Health Commission),…
The Spanish Medicines Market Today
9 February 2011
…market authorisation, pricing and reimbursement for medicines still are decided at national level, regions have been implementing their own policies intended to affect demand and shape the market. The change…